Nature Communications (Sep 2019)
Exploring use of unsupervised clustering to associate signaling profiles of GPCR ligands to clinical response
- Besma Benredjem,
- Jonathan Gallion,
- Dennis Pelletier,
- Paul Dallaire,
- Johanie Charbonneau,
- Darren Cawkill,
- Karim Nagi,
- Mark Gosink,
- Viktoryia Lukasheva,
- Stephen Jenkinson,
- Yong Ren,
- Christopher Somps,
- Brigitte Murat,
- Emma Van Der Westhuizen,
- Christian Le Gouill,
- Olivier Lichtarge,
- Anne Schmidt,
- Michel Bouvier,
- Graciela Pineyro
Affiliations
- Besma Benredjem
- Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal
- Jonathan Gallion
- Baylor College of Medicine
- Dennis Pelletier
- Pfizer Inc
- Paul Dallaire
- Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal
- Johanie Charbonneau
- CHU Sainte-Justine research center
- Darren Cawkill
- Pfizer Inc
- Karim Nagi
- College of Medicine, Member of QU Health, Qatar University
- Mark Gosink
- Pfizer Inc
- Viktoryia Lukasheva
- Institute for Research in Immunology and Cancer, Department of Biochemistry and Molecular Medicine, Université de Montréal
- Stephen Jenkinson
- Pfizer Inc
- Yong Ren
- Pfizer Inc
- Christopher Somps
- Pfizer Inc
- Brigitte Murat
- Institute for Research in Immunology and Cancer, Department of Biochemistry and Molecular Medicine, Université de Montréal
- Emma Van Der Westhuizen
- Institute for Research in Immunology and Cancer, Department of Biochemistry and Molecular Medicine, Université de Montréal
- Christian Le Gouill
- Institute for Research in Immunology and Cancer, Department of Biochemistry and Molecular Medicine, Université de Montréal
- Olivier Lichtarge
- Baylor College of Medicine
- Anne Schmidt
- Pfizer Inc
- Michel Bouvier
- Institute for Research in Immunology and Cancer, Department of Biochemistry and Molecular Medicine, Université de Montréal
- Graciela Pineyro
- Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal
- DOI
- https://doi.org/10.1038/s41467-019-11875-6
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 15
Abstract
Identifying ligands which activate the specific effectors driving particular in vivo drug effects remains challenging. Here, the authors apply unsupervised clustering of pharmacodynamic parameters to classify GPCR ligands into different categories with similar signaling profiles and shared frequency of report of side effects.
